Attributes of antiangiogenic factor plasminogen kringle 5 in glomerulonephritis

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 12, 2010, Pages 1804-1812

  Chen, Jin Shuen ^a   Hwang, Jyh Chang ^c   Chang, Li Chien ^b   Wu, Chia Chao ^a   Lin, Yuh Feng ^d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; CYCLINE; PEPTIDE FRAGMENT; PLASMINOGEN; PLASMINOGEN KRINGLE 5;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOPSY; DISEASE MODEL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; MOUSE; PATHOLOGY; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BIOPSY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PLASMINOGEN; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 78650497216     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13, 519 renal biopsies. Kidney Int. 2004;66(3):920-923.
2. Stewart JH, McCredie MR, Williams SM, Jager KJ, Trpeski L, McDonald SP; ESRD Incidence Study Group. Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrology. 2007;12(5):520-527.
3. Brady HR, O'meara YM, Brenner BM. Glomerular disease. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. Vol 2. 16th ed. Columbus, OH: McGraw-Hill Co; 2005:1674-1679.
4. Feehally J, Floege J, Savill J, Turner AN. Glomerular injury and glomerular response. In: Davison AM, Cameron JS, Grünfeld JP, Kerr DNS, Ritz E, Winearls CG, eds. Oxford Textbook of Clinical Nephrology. Vol 2. 3rd ed. New York, NY: Oxford University Press; 2005:363-373.
5. Perico N, Abbate M, Remuzzi G. More on renal disease progression: is interstitial inflammation truly protective? J Am Soc Nephrol. 2007;18(6):1824-1834.
6. Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13(3):806-816.
7. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003-2017.
8. Liu E, Morimoto M, Kitajima S, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol. 2007;18(7):2094-2104.
9. Tsokos M, Pufe T, Paulsen F, Anders S, Mentlein R. Pulmonary expression of vascular endothelial growth factor in sepsis. Arch Pathol Lab Med. 2003;127(3):331-335.
10. Kang DH, Anderson S, Kim YG, et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis. 2001;37(3):601-611.
11. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model, I: potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol. 2001;12(7):1434-1447.
12. Daniel C, Wiede J, Krutzsch HC, et al. Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int. 2004;65(2):459-468.
13. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol. 2007;171(4):1104-1112.
14. Taneda S, Pippin JW, Sage EH, et al. Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol. 2003;14(4):968-980.
15. Durvasula RV, Shankland SJ. Mechanical strain increases SPARC levels in podocytes: implications for glomerulosclerosis. Am J Physiol Renal Physiol. 2005;289(3):F577-F584.
16. Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma JX. Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol. 2006;17(2):475-486.
17. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol. 2004;286(5):F893-F902.
18. Cao Y, Xue L. Angiostatin. Semin Thromb Hemost. 2004;30(1):83-93.
19. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315-328.
20. Geiger JH, Cnudde SE. What the structure of angiostatin may tell us about its mechanism of action. J Thromb Haemost. 2004;2(1):23-34.
21. Nguyen TM, Subramanian IV, Kelekar A, Ramakrishnan S. Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood. 2007;109(11):4793-4802.
22. Perri SR, Martineau D, François M, et al. Plasminogen kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. Mol Cancer Ther. 2007;6(2):441-449.
23. Chen JS, Chen A, Chang LC, et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. Nephrol Dial Transplant. 2004;19(11):2721-2728.
24. Wang Y, Wang YP, Tay YC, Harris DC. Progressive Adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58(4):1797-1804.
25. Chen JS, Lee HS, Jin JS, et al. Attenuation of mouse mesangial cell contractility by high glucose and mannitol: involvement of protein kinase C and focal adhesion kinase. J Biomed Sci. 2004;11(2):142-151.
26. Sivridis E, Giatromanolaki A, Touloupidis S, Pasadakis P, Vargemezis V. Platelet endothelial cell adhesion molecule-1 and angiogenic factor expression in idiopathic membranous nephropathy. Am J Kidney Dis. 2003;41(2):360-365.
27. Rosso R, Lucioni M. Normal and neoplastic cells of brown adipose tissue express the adhesion molecule CD31. Arch Pathol Lab Med. 2006;130(4):480-482.
28. Naryzhny SN. Proliferating cell nuclear antigen: a proteomic view. Cell Mol Life Sci. 2008;65(23):3789-3808.
29. Durvasula RV, Shankland SJ. Models of Glomerulonephritis. New York, NY: Humana Press: 2002:47-66. Goligorsky MS, ed. Methods in Molecular Medicine: Renal Disease: Techniques and Protocols; vol 86.
30. Clement LC, Liu G, Perez-Torres I, Kanwar YS, Avila-Casado C, Chugh SS. Early changes in gene expression that influence the course of primary glomerular disease. Kidney Int. 2007;72(3):337-347.
31. Honkanen EO, Teppo AM, Grönhagen-Riska C. Decreased urinary excretion of vascular endothelial growth factor in idiopathic membranous glomerulonephritis. Kidney Int. 2000;57(6):2343-2349.
32. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003-2017.
33. Futrakul N, Butthep P, Futrakul P. Biomarkers of endothelial injury in focal segmental glomerulosclerotic nephrosis. Ren Fail. 2005;27(4):393-395.
34. Hertig A, Rondeau E. Role of the coagulation/fibrinolysis system in fibrinassociated glomerular injury. J Am Soc Nephrol. 2004;15(4):844-853.
35. Jancar S, Sánchez Crespo M. Immune complex-mediated tissue injury: a multistep paradigm. Trends Immunol. 2005;26(1):48-55.
36. Lentsch AB, Ward PA. Regulation of experimental lung inflammation. Respir Physiol. 2001;128(1):17-22.
37. Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res. 2005;65(11):4663-4672.
38. Gonzalez-Gronow M, Kalfa T, Johnson CE, Gawdi G, Pizzo SV. The voltage-dependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells. J Biol Chem. 2003;278(29):27312-27318.
39. Lu GY, Shen L, Wang ZY, et al. Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. Chin Med J. 2008;121(2):133-136.